-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today (February 9), the official website of the China National Medical Products Administration (NMPA) announced the latest announcement that the yttrium [90Y] resin microspheres (SIR-Spheres) declared by Grand Pharma have been approved in China
Screenshot source: NMPA official website
Liver cancer is one of the most lethal cancers in China, and Chinese liver cancer patients account for about 50% of global patients
In November 2020, Grand Pharma announced that its marketing authorization application for yttrium [90Y] resin microspheres was officially accepted by the NMPA
Yttrium [90Y] resin microspheres is a targeted internal radionuclide product for liver malignant tumors, which combines the dual advantages of radiopharmaceuticals and precision interventional therapy
Yttrium [90Y] resin microspheres were originally developed by Sirtex Medical, a global life science company in Australia.
In addition to yttrium [90Y] resin microspheres, an innovative radionuclide-conjugated drug (RDC), Grand Pharma has also entered into a number of transactions and cooperation agreements with Telix Pharmaceuticals, Jiangsu Institute of Atomic Medicine, and Poole Biosciences.
Reference source:
[1] On February 9, 2022, the release of the drug approval document pending collection.
[3] The marketing authorization application of Yuanda Pharmaceutical’s yttrium [90Y] resin microspheres was accepted by the China Food and Drug Administration.
